Methoxamine

Quick links to important sections

Methoxamine

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Methoxamine

Property Description
Active ingredient Methoxamine hydrochloride
Form Sterile Aqueous Solution (Injection)
Pharmacological class Selective alpha1-Adrenergic Receptor Agonist
Common use Rapidly raising low blood pressure (Antihypotensive)
Origin Synthetic organic compound

Defining Methoxamine: A Selective Sympathomimetic Amine

Methoxamine is a medicinal substance classified as a potent sympathomimetic amine, primarily recognized for its ability to rapidly counteract severe drops in blood pressure during acute medical events. It is a synthetic organic compound chemically derived from the phenethylamine structure, distinguishing it from naturally occurring catecholamines. This compound functions as a selective alpha1-adrenergic receptor agonist. Its effect is focused on increasing vascular tone while having negligible direct influence on cardiac beta-receptors. The medicine works by tightening blood vessels rather than significantly speeding up the heart, a feature that distinguishes it from less selective pressor agents.

Composition, Formulation, and Critical Use Profile

The active compound is Methoxamine, which is utilized as its stable salt, Methoxamine hydrochloride, and is formulated as a sterile, single-ingredient aqueous solution intended for parenteral administration (injection) in clinical settings. The drug is categorized under ATC code C01CA10, grouping it with other adrenergic and dopaminergic agents used for circulatory support. The general purpose of Methoxamine is to function as an antihypotensive agent or vasopressor, restoring systemic resistance to support blood flow to vital organs. Its formulation as an injectable solution reflects its use in controlled clinical environments for managing critical hypotensive crises.

Regulatory References

  1. Methoxamine - MeSH - NIH
  2. WHO ATC/DDD Index

What side effects are possible with Methoxamine?

Possible Side Effects and Safety Information

The safety profile for Methoxamine is defined by the consequences of its potent action on the circulatory system, as documented in official regulatory labeling. Adverse reactions are grouped by the body system affected, though standard frequency classifications (e.g., Common, Rare) are not typically applied in the primary government summaries. The risk profile centers on effects that arise from the severe increase in vascular tone.

Officially Documented Adverse Reactions

Adverse reactions listed in regulatory sources are classified by system-organ class, reflecting the drug's impact on various physiological systems:

  • Vascular and Cardiac Disorders: Includes undesirable or prolonged hypertension (high blood pressure), severe peripheral and visceral vasoconstriction, bradycardia (slow heart rate), and potential decreased cardiac output.
  • Nervous System Disorders: Documented effects include severe headache, restlessness, and nervousness.
  • Gastrointestinal and Renal Disorders: Reactions such as nausea, vomiting, and urinary urgency are noted.

Serious Adverse Reactions

The official safety information highlights reactions of critical clinical significance. These include the potential for cerebral hemorrhage and seizures as consequences of severe, uncontrolled hypertension. Additionally, fetal bradycardia is specifically documented as a serious risk associated with the drug's use in obstetrical settings.

Population-Specific Safety Statements

Regulatory documents include specific safety considerations for certain patient groups. The potential for decreased cardiac output is noted as particularly hazardous in older adult (geriatric) patients. Furthermore, peripheral and visceral vasoconstriction, along with reduced blood flow to the kidneys, is noted to be most likely to occur in hypovolemic patients (those with low blood volume). Safety constraints also include the potential for plasma volume depletion with prolonged use.

Overdose and Emergency Response

Overdose and when to seek help

Overdosage of Methoxamine hydrochloride is primarily defined by an exaggerated pressor effect, which leads to severe prolonged hypertension.

Documented Overdose Manifestations

Official regulatory documents list several clinical signs associated with overdosage. These manifestations include severe headache, severe bradycardia, nausea, vomiting (often projectile), restlessness, anxiety, weakness, dizziness, and precordial pain. The severe increase in blood pressure carries a risk of life-threatening outcomes, including seizures and cerebral hemorrhage.

Required Emergency Actions

The prescribing information mandates that caution be used to avoid overdosage. Immediate medical attention is required for any manifestations of severe prolonged hypertension, seizures, or signs of compromised organ perfusion. Urgent professional medical intervention is necessary to manage life-threatening complications.

Management involves symptomatic and supportive treatment. There is no specific antagonist documented for the primary pressor mechanism. However, bradycardia may be treated by administration of atropine, and management of severe hypertension may involve the use of short-acting alpha-receptor blocking agents. Geriatric patients may be especially susceptible to harm from the resulting decreased cardiac output.

Therapeutic Uses of Methoxamine

Quick Facts

  • Primary Therapeutic Domain: Supports blood pressure during acute hypotensive states.
  • Main Use: Manages low blood pressure associated with surgical procedures and various forms of shock.
  • Clinical Benefit: Helps restore or maintain adequate blood pressure and circulation to vital organs.

Methoxamine is a compound used in clinical settings for the management of acute hypotensive states, which refers to dangerously low blood pressure. The medication is an established therapeutic option to help restore and maintain blood pressure, particularly in scenarios where rapid support is needed.

Its uses are primarily indicated for the prevention and treatment of a hypotensive state that may arise during spinal anesthesia or as an adjunct to treatment for low blood pressure resulting from hemorrhage, drug reactions, surgical complications, or shock related to trauma or tumors affecting the brain. It is part of the overall care plan to support circulation and is administered under careful medical supervision. The intervention is intended to help ensure adequate perfusion to the body's essential systems.

Eligibility and Restrictions for Use

Methoxamine, an alpha-1 adrenergic agonist, is primarily used to manage hypotension (low blood pressure), often during or after anesthesia. Its use is determined by a healthcare provider who considers the patient's overall cardiovascular health and pre-existing conditions.

Patient Groups Who May Use Methoxamine

Methoxamine is indicated for patients experiencing hypotension, including those with:

  • Low blood pressure during or following spinal or epidural anesthesia.
  • Certain cases of paroxysmal supraventricular tachycardia (a type of rapid heart rhythm).
  • Hypotension associated with some types of shock.

Contraindications and Cautions

Methoxamine is generally contraindicated (should not be used) in patients with specific severe conditions due to the risk of exacerbating the underlying disease. It must be used with extreme caution in several other patient groups.

Condition Recommendation
Severe Hypertension Contraindicated; risk of excessive blood pressure elevation.
Ventricular Fibrillation Contraindicated.
Severe Coronary Artery Disease Use with extreme caution.
Hyperthyroidism Use with extreme caution.
Heart Block (partial) Use with extreme caution; can worsen existing bradycardia.
Pregnancy Use is generally avoided unless the potential benefit outweighs the risk to the fetus.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Methoxamine

Interaction scope

Medicinal product categories with documented interactions: Sympathomimetic-effect potentiators (e.g., MAOIs, Oxytocics), Pharmacodynamic antagonists (e.g., alpha- and beta-Adrenergic Antagonists), Cardiac Glycosides, and Regional Anesthetics.

Specific interacting medicines (if explicitly listed): Oxytocin, Methylergonovine, Ergonovine, Clonidine, Propofol, Atropine, Reserpine, Quinidine, Mephentermine, and Theophylline.

Mechanistic basis of interactions (only if stated in label): Pharmacodynamic potentiation and pharmacodynamic antagonism of the pressor effect.

Timing-based interaction rules (if applicable): None documented in official regulatory labeling.

Interaction-related restrictions: Restrictions are imposed to mitigate the risk of severe outcomes, specifically the risk of serious postpartum hypertension and stroke associated with co-administration of Methoxamine’s class and oxytocic drugs.

Interaction classifications (high-level)

Interaction severity classification (as defined in official documents): Includes interactions classified as significant clinical risk (e.g., oxytocic drug potentiation) and those with antagonism of the intended effect.

Regulatory basis (EMA / FDA / etc.): FDA / DailyMed.

Resulting interaction structure

Official interaction statements:

  • Co-administration with Oxytocin and other oxytocic drugs has been associated with serious postpartum hypertension and stroke, as the pressor effect is augmented.
  • The pressor effect is formally augmented by Monoamine Oxidase Inhibitors (MAOIs), Clonidine, Propofol, and Atropine.
  • The pressor effect is formally antagonized by alpha-adrenergic antagonists, beta-adrenergic antagonists, Reserpine, Quinidine, and Mephentermine.
  • Co-administration with Cardiac Glycosides may increase the possibility of arrhythmias.

Connection to the overall interaction profile: Regulatory documents define this product’s interaction structure primarily through pharmacodynamic changes. The profile is characterized by substances that severely potentiate the antihypotensive action and others that formally antagonize the intended pressure increase. The official record lacks explicit data on metabolic, transporter-based, food, or timing-dependent interactions.

Mechanism of Action

Molecular Specificity: Direct alpha1-Adrenergic Agonism

Methoxamine is a direct-acting selective agonist for the alpha1-Adrenergic Receptor, the primary molecular target responsible for controlling peripheral vascular tone. Its mechanism focuses exclusively on activating this receptor, thereby initiating the key intracellular signals, such as the activation of the Gq/ PLC pathway and subsequent calcium mobilization, while maintaining negligible activity at beta-Adrenergic Receptors. This selective targeting is a primary determinant of the entire downstream physiological response.


Causal Cascade: Vascular Resistance and Pressure Modulation

The alpha1-mediated calcium surge results in powerful and widespread contraction of vascular smooth muscle in both arteries and veins. This cellular effect rapidly translates into a significant increase in Systemic Vascular Resistance (SVR), a mechanical force that raises both systolic and diastolic blood pressure. The ensuing pressure elevation activates the body’s homeostatic baroreceptor reflex, which results in a reflex deceleration of the heart rate (bradycardia).


️ Mechanistic Constraint: Afterload and Flow Regulation

The mechanism increases resistance, but the resulting high SVR imposes a constraint known as increased cardiac afterload. This resistance increases mechanical work, which can result in a reduction of functional output. Furthermore, the generalized nature of the vasoconstriction mechanism leads to altered blood flow distribution, including a reduction in perfusion to specific vascular beds such as the renal or splanchnic circulation.

Dosage and Administration Information

How to use Methoxamine

Methoxamine hydrochloride is a medication administered solely by injection in a controlled clinical setting, primarily for the management of acute drops in blood pressure. Usage involves a precise procedural structure centered on intravenous administration and individualized dose adjustment.


Administration and Dosing Protocol

Feature Administration Summary
Route and Method The medicine is administered via Intravenous (IV) Bolus Injection.
Standard Initial Dose The typical starting dose is 4.7 mg to 9.4 mg by IV bolus.
Dosing Schedule Doses are administered as needed and must be titrated to the blood pressure goal to ensure the intended effect is reached.
Maximum Total Dose The total dosage for a single treatment event must not exceed 47 mg.

Preparation and Handling Requirements

Methoxamine is available in various strengths, and the preparation method depends on the concentration. The high-concentration 47 mg/mL strength must be diluted before IV administration using compatible solutions such as 0.9% Sodium Chloride Injection or 5% Dextrose Injection. Conversely, the 4.7 mg/mL premixed strength must not be diluted. Before use, the solution must be visually inspected for clarity and the absence of particulate matter.

The protocol for administering the medicine defines the required IV route and the necessity of titration to ensure delivery during acute intervention.

Recent Clinical Evidence

Methoxamine is an alpha-1 adrenergic receptor agonist primarily studied for its potent vasoconstrictive effect, leading to an increase in both systolic and diastolic blood pressure. Its historical use and current research focus on the management of acute hypotension, particularly in surgical settings or shock.

Use in Acute Hypotension

Clinical trials have investigated Methoxamine's role in maintaining hemodynamic stability during anesthesia, such as epidural or spinal anesthesia, where low blood pressure is a common complication. Studies have examined its ability to elevate systemic blood pressure, which subsequently activates the baroreflex, causing a compensatory decrease in heart rate (reflex bradycardia).

Methoxamine's profile as a relatively pure alpha-1 agonist means it primarily affects the peripheral vascular system without significantly stimulating cardiac beta-receptors, an aspect evaluated in trials comparing it to less selective pressor agents.

Research in Specific Populations

Recent randomized controlled trials have focused on specific demographics. One study, for instance, investigated the effect of Methoxamine infusion on elderly patients undergoing hip-joint replacement surgery. The research examined the drug's influence on maintaining stable blood pressure and observed outcomes related to myocardial health and postoperative cognitive function.

Another area of limited research has explored the use of inhaled Methoxamine to enhance exercise performance in a small cohort of patients with impaired left ventricular function, suggesting potential effects on airway vasculature. However, this application remains outside the drug's conventional use and requires further large-scale investigation to clarify its clinical relevance.

Frequently Asked Questions (FAQ)

Common questions about Methoxamine (FAQ)

Q: Is Methoxamine a type of stimulant medication?

Official information classifies Methoxamine as a sympathomimetic amine. This means it affects the sympathetic nervous system and functions to constrict blood vessels. However, official documentation indicates that unlike some other drugs in this class, Methoxamine has little direct stimulating effect on the central nervous system.

Q: How is Methoxamine different from other pressor agents like Phenylephrine?

Studies and official product information indicate that Methoxamine has a slower time course compared to other pressor agents like Phenylephrine. This means the time it takes for the effect to begin and the time it takes for the effect to fade are often longer. It is also described as generally less potent.

Q: What are the most common or mild side effects reported for Methoxamine?

According to official regulatory information, commonly reported effects include hypertension (high blood pressure) and a slow heart rate, known as reflex bradycardia. Symptoms affecting the digestive and nervous systems may also be reported, such as gastrointestinal issues, anxiety, or urinary problems.

Q: Is a headache a common side effect of Methoxamine?

Headache is listed as a documented adverse reaction associated with Methoxamine in official safety information. Clinical observations note that headache is often reported and can be severe.

Q: How is Methoxamine chemically related to other substances like amphetamines?

Methoxamine is chemically derived from a basic structure known as the phenethylamine structure. This structure is the parent compound for a variety of other medicinal and non-medicinal substances, including those chemically related to amphetamines.

Q: How long does it typically take for Methoxamine's effect to begin?

Official pharmacological data indicates that when Methoxamine is administered intravenously (IV), its blood pressure-raising effect typically begins rapidly, within one to two minutes.

Q: What is the expected duration of Methoxamine’s action in the body?

Following a single intravenous (IV) injection, regulatory data indicates that the action of Methoxamine lasts for approximately 60 minutes.

Q: Is Methoxamine still widely used in modern clinical practice?

Official drug registries and medical sources indicate that Methoxamine has been mostly or entirely discontinued from widespread use in modern clinical settings. Its use is now considered rare or limited in many regions.

Q: Why is Methoxamine sometimes said to be obsolete?

The drug is sometimes referred to as obsolete because medical sources confirm that it has been largely or entirely discontinued from routine clinical use. This is often due to the availability of newer treatment options.

Q: What should be monitored by healthcare providers when a patient is using Methoxamine?

Due to the potential for severe effects like excessive high blood pressure (hypertension) and a slow heart rate (reflex bradycardia), monitoring the patient’s blood pressure and heart rate is standard practice during and after administration. This monitoring ensures the medication is adjusted safely to achieve the correct blood pressure goal.

Q: Are there any known interactions between Methoxamine and non-prescription medications, like cold remedies?

Official interaction information indicates that Methoxamine’s pressor effect can be enhanced by sympathomimetic agents found in many non-prescription cold remedies, such as Phenylephrine. Combining these may increase the risk of an excessive elevation in blood pressure.

Q: Are there any food or alcohol interactions listed for Methoxamine?

Regulatory information specifically notes that both Methoxamine and high-caffeine products can increase blood pressure. Combining these substances may enhance the blood pressure-raising effects of the medicine.

Q: Are there different trade names for Methoxamine, such as Vasoxyl?

Yes, Methoxamine hydrochloride has been marketed under various trade names throughout its history. These have included Vasoxyl, Vasoxine, and Vasylox.

Q: Are there any known disease interactions with Methoxamine, such as dehydration?

Low blood volume, known as hypovolemia, is listed as a precaution in the official product information. The documentation notes that the potent vasoconstriction effect of the drug is most likely to occur in patients with low blood volume.

Q: Is there a risk of tissue damage if Methoxamine is not administered properly?

Extravasation, which means the solution leaks outside the vein during injection, is listed as a safety precaution in official labeling. Official documents note that an antidote called phentolamine is available to manage potential tissue issues resulting from this complication.

Q: Why is Methoxamine sometimes confused with the street drug 'Methoxetamine' (MXE)?

The confusion arises primarily due to the similar-sounding names. Regulatory classification indicates that Methoxamine is a potent pressor agent (vasopressor) used for low blood pressure, while Methoxetamine (MXE) is an entirely different substance classified as a dissociative hallucinogen.

How should Methoxamine be stored and disposed of?

How to Store and Dispose of Methoxamine

The storage and disposal requirements for Methoxamine hydrochloride injection are defined by regulatory labeling to maintain product stability and safety.

Storage Requirement Condition
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Must be protected from light and kept in the original container.
Prohibited Do not freeze the sterile aqueous solution.
Child Safety Keep out of the sight and reach of children.
Disposal Requirement Condition
Protocol Dispose of unused or expired product according to local regulations for pharmaceutical waste.
Restriction Do not dispose of medicine in household trash, sinks, or toilets.

Storage conditions are designed to maintain the drug’s potency and integrity, while disposal protocols are mandated to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Methoxamine found in:

A-Z Index: